Lupin shares jump after securing USFDA approval for Brivaracetam oral solutionLupin shares jump after securing USFDA approval for Brivaracetam oral solution

Introduction

Leading pharmaceutical company received U.S. FDA approval for Brivaracetam Oral Solution 10 mg/mL and launched the treatment for partial-onset seizures in United States market nationwide.

Also Read: One Mobikwik Systems jumps 13% after subsidiary gets BSE nod to launch broking operations

Share price movement of Lupin

On February 25, 2026, Lupin Ltd opened at ₹2,254.65, up 0.16% from its previous close of ₹2,251.10. The stock reached a high of ₹2,278.00 (1.19%) and a low of ₹2,254.65. By 11:12 AM, it traded at ₹2,275.75, a 1.10% increase, with a market cap of ₹1,04,011.61 crore.

Lupin Launches Brivaracetam in US

Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application for Brivaracetam Oral Solution 10 mg/mL. The company has initiated the product launch in the United States market.

Brivaracetam Oral Solution is bioequivalent to Briviact Oral Solution 10 mg/mL. It is indicated for partial-onset seizures in patients aged one month and older. The reference drug recorded USD 135 million annual U.S. sales.

Stock performance of Lupin for period of 1 week, 6 months, and 1 year

Lupin Ltd delivered a 1.06% return over the past week and gained 18.8% in the past 6 months. The stock rose 18.5% over the past 1 year.

Also Read: Waaree Energies in green on securing 500MW solar module order; check details

Shareholding pattern of Lupin

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	47%	47%	47%
FII	21.50%	20.50%	21.30%
DII	26%	26.60%	25.60%
Public	6.00%	6%	6.30%

About Lupin

Lupin Limited (NSE: LUPIN) is a Mumbai-based global pharmaceutical company operating in 100 markets, specializing in branded and generic formulations, biotechnology products, and APIs.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs